Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology and founded by experienced industry professionals Tom McCarthy (Executive Chairman), former President and CEO of Spinifex Pharmaceuticals and Peter Joyce (CEO), formerly Project Leader at Vertex Pharmaceuticals. Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cells, illuminating them for attack and destruction by the immune system. We are targeting the endoplasmic reticulum aminopeptidase (ERAP1) in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells, thus dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology. Grey Wolf is working with leading academic and commercial drug discovery partners to deliver a clinical candidate against a strongly validated target.
Hover over each of the interactive dots to learn more about the antigen presentation pathway
Multiple sources of protein that feed the antigen presentation pathway.
The majority of peptides that feed the antigen presentation pathway are degraded by the proteasome.
Peptides generated by the proteasome are transported into the ER.
Peptides from the cytosol are transported into the ER via the TAP transporter complex.
ER resident aminopeptidases which trim or over-trim antigens and neoantigens prior to loading onto MHC Class I. ERAP1 and ERAP2 have different peptide specificities.
At the cell surface the MHC Class I complex presents antigens / neoantigens to CD8 T cells where they are recognised as ‘self’ or 'non-self’.
Peptides loaded onto the MHC Class I complex through the action of the Peptide Loading Complex (PLC) and ERAP1/2 activity are transported to the cell surface.